1998
Financial Statements
| The following information is excerpted from Noven's 1998 Annual Report to Shareholders. |
|
Back
Notes
to Financial Statements
Years
Ended December 31, 1998, 1997 and 1996
Segment, Geographic and Customer Data
Noven is engaged principally in one line of business, the development and commercialization of advanced transdermal drug delivery systems, which represents more than 90% of the total revenue. Products that are sold to RPR for resale in Europe are shipped to Ireland. There were no sales or transactions among geographic areas.
The following table presents information about Noven by geographic area:
|
1998 |
1997 |
1996 |
|
 |
|||
| (in
thousands)
Revenues |
|||
| United States |
$16,256 |
$ 6,417 |
$13,877 |
| Ireland |
5,586 |
7,850 |
6,590 |
| Total Revenue |
$21,842 |
$14,267 |
$20,467 |
Total revenue by customers
of Noven, include royalty payments and license revenue:
|
1998 |
1997 |
1996 |
|
|
|||
| (in
thousands)
Novartis |
$ 3,168 |
$ 5,017 |
$13,728 |
| RPR |
11,677 |
7,850 |
6,001 |
| Vivelle Ventures LLC |
5,611 |
— |
— |
| Other |
1,386 |
1,400 |
738 |
| Total Revenue |
$21,842 |
$14,267 |
$20,467 |
Copyright © 1999 Noven Pharmaceuticals, Inc. All rights reserved.